recombinant vaccinia prostate-specific antigen vaccine

BIOLOGICAL4 trials

Sponsors

Eastern Cooperative Oncology Group, National Cancer Institute (NCI)

Conditions

Adenocarcinoma of the ProstateProstate CancerRecurrent Prostate CancerStage IV Prostate Cancer

Phase 2

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

CompletedNCT00045227

National Cancer Institute (NCI)Prostate Cancer

Start: 2002-08-31End: 2007-10-31Updated: 2013-06-19

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

TerminatedNCT00005039

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer

Start: 2000-01-31Updated: 2013-01-24

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

CompletedNCT00020254

National Cancer Institute (NCI)Prostate Cancer

Start: 2000-06-30Updated: 2015-04-29

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

CompletedNCT00003871

Eastern Cooperative Oncology GroupProstate Cancer

Start: 1999-09-24Target: 60Updated: 2023-06-22